APC.H — Advanced Proteome Therapeutics Income Statement
0.000.00%
FinancialsHighly SpeculativeMicro Cap
Annual income statement for Advanced Proteome Therapeutics, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2018 July 31st | 2019 July 31st | 2020 July 31st | 2021 July 31st | 2022 July 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.17 | 0.936 | 0.57 | 0.657 | 0.96 |
Operating Profit | -1.17 | -0.936 | -0.57 | -0.657 | -0.96 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.893 | -0.461 | -0.541 | -1.92 | 0.597 |
Net Income After Taxes | -0.893 | -0.461 | -0.541 | -1.92 | 0.597 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.745 | -0.333 | -0.451 | -1.83 | 0.76 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.745 | -0.333 | -0.451 | -1.83 | 0.76 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.05 | -0.019 | -0.02 | -0.06 | 0.019 |